Cardiovascular prostheses

Patent metadata

Field	Value
Publication number	US-9867906-B2
Application number	US-201615386902-A
Country	US
Kind code	B2
Filing date	Dec 21, 2016
Priority date	Dec 16, 2011
Publication date	Jan 16, 2018
Grant date	Jan 16, 2018

Abstract

Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.

First claim

What is claimed is:

1. A particulate biomaterial for treating damaged cardiovascular tissue, consisting of:
a plurality of particulate structures, each of said plurality of particulate structures consisting of first and second tissue remodeling inducing components,
said first tissue remodeling inducing component consisting of a particulate extracellular matrix (ECM) component consisting of an ECM composition, said ECM composition consisting of acellular ECM,
said second tissue remodeling inducing component consisting of an ECM-mimicking biomaterial component, said ECM-mimicking biomaterial component consisting of a biomaterial composition, said biomaterial composition consisting of poly(glycerol sebacate),
said particulate ECM component being encased in said poly(glycerol sebacate) component, wherein said plurality of particulate structures comprise an acellular ECM core with a poly(glycerol sebacate) outer layer,
said poly(glyceraol sebacate) component being adapted to modulate degradation of said encased particulate ECM component, wherein each of said plurality of particulate structures exhibits a linear degradation profile in vivo,
said particulate ECM component and said poly(glyceraol sebacate) component being adapted to jointly induce remodeling of damaged biological tissue when delivered thereto,
each of said plurality of particulate structures being further adapted to modulate inflammation of damaged biological tissue and induce regeneration of new tissue and tissue structures with site specific structural and functional properties, when delivered to said damaged biological tissue.

2. The particulate biomaterial of claim 1 , wherein said acellular ECM is derived from a mammalian tissue source is selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), urinary basement membrane (UBM), liver basement membrane (LBM), stomach submucosa (SS), mesothelial tissue, placental tissue and cardiac tissue.

Assignees

• Cormatrix Cardiovascular Inc

Inventors

• Matheny Robert G

Classifications

• A61L2300/41

  Anti-inflammatory agents, e.g. NSAIDs · CPC title

• A61L27/54 Primary

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61F2/06

  Blood vessels · CPC title

• A61L27/18

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds · CPC title